CALL - SPRINTER OPEN END - ELI LILLY & CO | Delayed Deutsche Boerse AG 05:13:00 27/06/2024 pm IST | ||
| 53.24 EUR | +0.55% |
|
| Current month | +19.07% | ||
| 1 month | +20.20% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 27/24/27 | 53.24 | +0.55% |
| 26/24/26 | 52.95 | -0.43% |
| 25/24/25 | 53.18 | +0.95% |
| 24/24/24 | 52.68 | +1.78% |
| 21/24/21 | 51.76 | +2.56% |
Delayed Quote Deutsche Boerse AG
Last update June 27, 2024 at 05:13 pm IST
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Vontobel
|
| WKN | VU6E9C |
| ISIN | DE000VU6E9C5 |
| Date issued | 18/04/2023 |
| Strike | 334.8 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 6.51 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 53.67 € |
|---|---|
| Lowest since issue | 5.89 € |
| Spread | 0.22 € |
| Spread % | 0.41% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
901.3
USD
Average target price
860.5
USD
Spread / Average Target
-4.52%
- Stock Market
- Certificates
- Certificat
